Kura Oncology (KURA) Non-Current Assets (2014 - 2026)
Kura Oncology (KURA) posted quarterly Non-Current Assets of $28.8 million for Q1 2026, up 47.04% year-over-year from $19.6 million in Q1 2025, and down 3.13% quarter-over-quarter from $29.7 million in Q4 2025.
Kura Oncology (KURA) Non-Current Assets (2014 - 2026) Analysis & Trends
Kura Oncology (KURA) has reported Non-Current Assets for 13 consecutive years, with $28.8 million the latest figure, recorded in Q1 2026.
- In Q1 2026, Non-Current Assets rose 47.04% year-over-year to $28.8 million; the TTM figure through Mar 2026 stood at $109.5 million (up 66.24% YoY), while the FY2025 annual figure was $29.7 million, up 93.74% from the prior year.
- Non-Current Assets retreated to $28.8 million in Q1 2026 per KURA's latest filing, from $29.7 million in the prior quarter.
- Across five years, Non-Current Assets topped out at $29.7 million in Q4 2025 and bottomed at $9.1 million in Q2 2023.
- Historically, Non-Current Assets has averaged $16.8 million across 5 years, with a median of $15.3 million in 2024.
- Annual changes were most pronounced in 2023 — Non-Current Assets declined 21.89% — and 2025, when it soared 93.74%.
- Kura Oncology's Non-Current Assets stood at $9.9 million in 2022, then jumped by 66.54% to $16.5 million in 2023, then slipped by 6.83% to $15.3 million in 2024, then jumped by 93.74% to $29.7 million in 2025, then declined by 3.13% to $28.8 million in 2026.
- Business Quant data shows KURA's Non-Current Assets at $28.8 million in Q1 2026, $29.7 million in Q4 2025, and $28.7 million in Q3 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Non-Current Assets (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 128.13 Bn | 120.28 Bn | 2.84 Bn | 14.88 Bn |
| 2 | Regeneron Pharmaceuticals | 112.33 Bn | 104.33 Bn | 3.93 Bn | 23.28 Bn |
| 3 | Argenx Se | 53.24 Bn | 48.05 Bn | 1.41 Bn | 1.96 Bn |
| 4 | Revolution Medicines | 43.64 Bn | 43.64 Bn | - | 294.93 Mn |
| 5 | BeOne Medicines | 39.27 Bn | 34.17 Bn | 1.53 Bn | 1.96 Bn |
| 6 | MindWalk Holdings | 35.32 Bn | 35.31 Bn | 1.82 Bn | 3.76 Mn |
| 7 | Royalty Pharma | 33.72 Bn | 35.84 Bn | - | 18.06 Bn |
| 8 | Alnylam Pharmaceuticals | 30.58 Bn | 27.27 Bn | 992.69 Mn | 938.60 Mn |
| 9 | Insmed | 27.01 Bn | 25.85 Bn | 358.27 Mn | 468.65 Mn |
| 10 | Kura Oncology | 966.11 Mn | 966.11 Mn | 20.63 Mn | 28.35 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | 28.35 Mn |
| Mar 31, 2026 | 28.77 Mn |
| Dec 31, 2025 | 29.70 Mn |
| Sep 30, 2025 | 28.72 Mn |
| Jun 30, 2025 | 22.35 Mn |
| Mar 31, 2025 | 19.57 Mn |
| Dec 31, 2024 | 15.33 Mn |
| Sep 30, 2024 | 15.65 Mn |
| Jun 30, 2024 | 15.35 Mn |
| Mar 31, 2024 | 16.07 Mn |
| Dec 31, 2023 | 16.45 Mn |
| Sep 30, 2023 | 13.85 Mn |
| Jun 30, 2023 | 9.09 Mn |
| Mar 31, 2023 | 9.53 Mn |
| Dec 31, 2022 | 9.88 Mn |
| Sep 30, 2022 | 11.60 Mn |
| Jun 30, 2022 | 11.64 Mn |
| Mar 31, 2022 | 11.55 Mn |
| Dec 31, 2021 | 11.76 Mn |
| Sep 30, 2021 | 12.24 Mn |